AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02812056
Drug: TAK-228
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase.
Trial: NCT01465763
Drug: tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg oral BID
Trial: NCT00770900
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children \>15 years took 10mg tablet of montelukast
Trial: NCT01173068
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
Trial: NCT00617929
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
Trial: NCT01030432
Drug: BMS-650032
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 200 mg, Twice Daily, 48 weeks
Trial: NCT01030432
Drug: BMS-650032
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
Trial: NCT01030432
Drug: Peginterferon Alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
Trial: NCT01030432
Drug: Peginterferon Alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
Trial: NCT01030432
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
Trial: NCT01030432
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
Trial: NCT01046006
Drug: Bortezomib, Rituximab, Dexamethasone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv
Trial: NCT02987244
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose.
Trial: NCT00250432
Drug: caspofungin acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
Trial: NCT01082237
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
Trial: NCT00108745
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00108745
Drug: Paclitaxel Poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00002489
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002489
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002489
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00135681
Drug: nedocromil budesonide
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02903017
Drug: Tranexamic acid 5%
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Via nasogastric tube, 100 mL
Trial: NCT00243074
Drug: cediranib maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00847522
Drug: Fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
Trial: NCT03197766
Drug: BMN 111
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 15 μg/kg of BMN 111 daily
Trial: NCT02908763
Drug: peginterferon alfa
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Trial: NCT02002377
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
Trial: NCT05038605
Drug: Topical metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of metronidazole cream on the anal verge every 8 hours after surgery
Trial: NCT05038605
Drug: oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
Trial: NCT03455270
Drug: G1T48
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral SERD
Trial: NCT03455270
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK 4/6 Inhibitor
Trial: NCT03534895
Drug: Midazolam Injectable Solution
RxNorm normalized name: midazolam Injectable Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous
Trial: NCT00602849
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01782690
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
Trial: NCT01782690
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
Trial: NCT03394677
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator - ointment twice daily (BID) for 4 weeks.
Trial: NCT02902770
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Trial: NCT02902770
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ketorolac 30mg push
Trial: NCT02902770
Drug: Normal Saline Drip
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Drip Placebo given over 10 minutes
Trial: NCT02902770
Drug: Normal Saline Push
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Push Placebo
Trial: NCT02304081
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
Trial: NCT02304081
Drug: Placebo for Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02987244
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epirubicin (70mg/m2)was administered intravenously on d1;
Trial: NCT04678531
Drug: Swabs containing tea tree oil and chamomile oil
DrugBank: Tea tree oil (DB11218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
Trial: NCT00609856
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet, 30 mg, once daily, 26 weeks
Trial: NCT00609856
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
Trial: NCT00003622
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003622
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03662269
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo (20mg, qd, po, 14days)
Trial: NCT01197612
Drug: pulmicort
RxNorm normalized name: Pulmicort
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: applied to nasal packing after surgery
Trial: NCT01056718
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
Trial: NCT01652820
Drug: Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01652820
Drug: Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03739320
Drug: Mepolizumab 100 MG Injection [Nucala]
RxNorm normalized name: mepolizumab 100 MG Injection [Nucala]
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 milligrams subcutaneously once every 4 weeks
Trial: NCT00487825
Drug: Canakinumab (investigational)
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Trial: NCT02987244
Drug: Vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vindesine (4mg)was administered intravenously on d1;
Trial: NCT03153150
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT03153150
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT02987244
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: etoposide (100mg) was administered intravenously on d1,2,3.
Trial: NCT03153150
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT03153150
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT03153150
Drug: Phenindione
RxNorm normalized name: phenindione
DrugBank: Phenindione (DB00498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT03153150
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Trial: NCT02344589
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: used for the active blocks
Trial: NCT02344589
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: used for the placebo-block
Trial: NCT02419417
Drug: BMS-986158
RxNorm normalized name: BMS-986158
DrugBank: BMS-986158 (DB15435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00663975
Drug: DCI 1020
RxNorm normalized name: DCI
DrugBank: Dichloroisoproterenol (DB12803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules (4,000 units of lipase) will be administered with meals and snacks
Trial: NCT02568397
Drug: Lanabecestat
RxNorm normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02568397
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03708497
Drug: carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
Trial: NCT02987244
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisone (60mg/m2)was administered intravenously by oral d1-5.
Trial: NCT03708497
Drug: Tranexamic acid plus misoprostol
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
Trial: NCT03708497
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
Trial: NCT04601324
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be required to use fluticasone propionate nasal spray twice daily.
Trial: NCT04601324
Drug: Azelastine hydrochloride and fluticasone propionate
RxNorm normalized name: AZELASTINE HYDROCHLORIDE 137 ug / FLUTICASONE PROPIONATE 50 ug NASAL SPRAY, METERED [AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE]
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
Trial: NCT04601324
Drug: Rupatadine
RxNorm normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rupatadine once daily for a total of 2 weeks.
Trial: NCT02904109
Drug: Triflusal
RxNorm normalized name: Triflusal
DrugBank: Triflusal (DB08814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
Trial: NCT01443403
Drug: Naldemedine
RxNorm normalized name: Naldemedine
DrugBank: Naldemedine (DB11691)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naldemedine tablets administered orally once a day.
Trial: NCT01482936
Drug: Oxycodone (OxyNorm®) Injection
RxNorm normalized name: oxycodone hydrochloride Oral Capsule [Oxynorm]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
Trial: NCT01925261
Drug: TPX-100 50mg
RxNorm normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01925261
Drug: TPX-100 100mg
RxNorm normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01925261
Drug: TPX-100 200mg
RxNorm normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01925261
Drug: TPX-100 20mg
RxNorm normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00403975
Drug: diquafosol tetrasodium ophthalmic solution, 2%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284232
Drug: Insulin dosing based on SMBG chart and education
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00476242
Drug: Vivitrol
RxNorm normalized name: Vivitrol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
Trial: NCT00476242
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
Trial: NCT01621243
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Trial: NCT01621243
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Trial: NCT01621243
Drug: Necuparanib
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib will be dosed daily